News

Regulatory decisions, clinical data, congress presentations and company updates

All Clinical data Company Congress Regulatory

09/022026

Clinical data Featured

NEJM publishes Phase 1/2 data on daraxonrasib in RAS-mutant non-small cell lung cancer

Among 38 previously treated patients with RAS-mutant NSCLC in the 160–220 mg dose group, the objective response rate was 42%, median progression-free survival 8.3 months and median overall survival 16 months.

Source: NEJM / Medical Xpress

04/132026

Clinical data

Phase 3 RASolute 302 meets its primary endpoint: overall survival significantly extended

Revolution Medicines announced an "unprecedented" overall survival benefit for daraxonrasib in the Phase 3 trial in previously treated metastatic pancreatic cancer: median OS 13.2 vs 6.7 months.

Source: Revolution Medicines / CancerNetwork